Glox Therapeutics Awarded Share of £3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate
• £500K grant to advance discovery and development of effective precision antibiotics targeting antimicrobial-resistant lung infections in people with cystic fibrosis
• Programme delivered by CF AMR Syndicate offers cross-sector collaboration and support to address urgent unmet need